MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

MediciNova Inc

Slēgts

SektorsVeselības aprūpe

1.31 -6.43

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.27

Max

1.39

Galvenie mērījumi

By Trading Economics

Ienākumi

38K

-2.8M

EPS

-0.06

Darbinieki

13

EBITDA

125K

-3.2M

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-15M

72M

Iepriekšējā atvēršanas cena

7.74

Iepriekšējā slēgšanas cena

1.31

Ziņu noskaņojums

By Acuity

42%

58%

153 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

MediciNova Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 2. apr. 23:55 UTC

Karstas akcijas

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2025. g. 2. apr. 22:50 UTC

Galvenie tirgus virzītāji

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2025. g. 2. apr. 21:08 UTC

Peļņas

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2025. g. 2. apr. 21:00 UTC

Peļņas

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2025. g. 2. apr. 23:56 UTC

Tirgus saruna

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2025. g. 2. apr. 23:44 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 2. apr. 23:44 UTC

Tirgus saruna

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2025. g. 2. apr. 23:44 UTC

Top Ziņas

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2025. g. 2. apr. 23:12 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 2. apr. 23:12 UTC

Tirgus saruna

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2025. g. 2. apr. 23:10 UTC

Tirgus saruna

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2025. g. 2. apr. 23:09 UTC

Tirgus saruna

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2025. g. 2. apr. 23:09 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 22:57 UTC

Tirgus saruna

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2025. g. 2. apr. 22:56 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 22:56 UTC

Tirgus saruna

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2025. g. 2. apr. 22:43 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2025. g. 2. apr. 22:12 UTC

Tirgus saruna

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2025. g. 2. apr. 21:48 UTC

Top Ziņas

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2025. g. 2. apr. 21:41 UTC

Tirgus saruna

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2025. g. 2. apr. 21:04 UTC

Top Ziņas

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2025. g. 2. apr. 21:03 UTC

Tirgus saruna

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2025. g. 2. apr. 20:53 UTC

Peļņas

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2025. g. 2. apr. 20:52 UTC

Peļņas

Kaiser Aluminum Changes Inventory Acctg Methodology

Salīdzinājums

Cenas izmaiņa

MediciNova Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 1.4505Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

153 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.